The drugs giant has signed a series of for-profit agreements for next year, and expects to make a modest income from the vaccine, it said.
The company had previously said it would only start to make money from the vaccine when Covid-19 was no longer a pandemic.
Its chief executive Pascal Soriot said the disease was becoming endemic.
The jab will continue to be supplied on a not-for-profit basis to poorer countries.
Mr Soriot had said previously: “We decided to provide it at no profit, because our top priority was to protect global health.”
He told the BBC he had “absolutely no regrets” about not making a profit when competitors had been, despite having to deal with political criticism in various countries.
He said the vaccine, which was developed with the University of Oxford, had saved a million lives around the world.
“I absolutely don’t regret it,” Mr Soriot said. “We are proud as a company of the impact we have had – we’ve saved millions of hospitalisations. The [AstraZeneca] team continues to do a stellar job.”
He said that the contracts that had been signed are for next year, adding: “The virus is becoming endemic which means we have to learn to live with it.
“We started this to help, but we said we would transition [to making a profit on the vaccine],” he said. “It’s not something we see as a huge profit-earner.”
There will be tiered pricing for countries to make sure the vaccine is affordable, Mr Soriot said.
By the end of the year AstraZeneca expects to have supplied 250 million doses of its vaccine to the Covax programme for developing countries.
Other vaccine manufacturers including Pfizer and Moderna have been making profits from their vaccines.
“This moment was always going to come – and it’s exactly why public health experts have demanded a waiver of intellectual property on Covid-19 vaccines,” he said.
“Covid-19 vaccine sales in [the fourth quarter of 2021] are expected to be a blend of the original pandemic agreements and new orders, with the large majority coming from pandemic agreements.”
By the end of September, AstraZeneca and its sub-licensees had supplied 1.5 billion doses.
The company reported revenues for the first nine months of the year of $25.4bn (£19bn), but said its overall profit margins had declined, mainly due to providing the Covid-19 vaccine at cost price.
Shares in the drugs giant fell more than 4% on Friday.
Meanwhile, another company that has developed a Covid vaccine, US giant Johnson & Johnson, said on Friday that it would split its consumer healthcare division, which makes products including Baby Powder and Listerine, from its drugs and medical devices businesses.
“The new Johnson & Johnson and the new consumer health company would each be able to more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value,” said Joaquin Duato, who is expected to become chief executive in January.